<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0196436</article-id>
<article-id pub-id-type="publisher-id">PONE-D-18-02926</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Dementia</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Dementia</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodegenerative diseases</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Cytoskeletal proteins</subject><subj-group><subject>Tubulins</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodegenerative diseases</subject><subj-group><subject>Movement disorders</subject><subj-group><subject>Parkinson disease</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Antibodies</subject><subj-group><subject>Autoantibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Antibodies</subject><subj-group><subject>Autoantibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject><subj-group><subject>Autoantibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject><subj-group><subject>Autoantibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject><subj-group><subject>Autoantibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodegenerative diseases</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Brain damage</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Probability theory</subject><subj-group><subject>Statistical distributions</subject><subj-group><subject>Distribution curves</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Tubulin and Tau: Possible targets for diagnosis of Parkinson’s and Alzheimer’s diseases</article-title>
<alt-title alt-title-type="running-head">AIAs for PD and AD</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1644-0273</contrib-id>
<name name-style="western">
<surname>Salama</surname>
<given-names>Mohamed</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Shalash</surname>
<given-names>Ali</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Magdy</surname>
<given-names>Alshimaa</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Makar</surname>
<given-names>Marianne</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Roushdy</surname>
<given-names>Tamer</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Elbalkimy</surname>
<given-names>Mahmoud</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Elrassas</surname>
<given-names>Hanan</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Elkafrawy</surname>
<given-names>Passent</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Mohamed</surname>
<given-names>Wael</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Abou Donia</surname>
<given-names>Mohamed B.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Medical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura, Egypt</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Toxicology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Biochemistry Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Okasha Institute of Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Faculty of Science, Menoufia University, Shebeen Elkoum, Egypt</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Department of Pharmacology, Faculty of Medicine, Menoufia University, Shebeen Elkoum, Egypt</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>Basic Medical Science Department, Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan Pahang, Malaysia</addr-line></aff>
<aff id="aff009"><label>9</label> <addr-line>Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Kobeissy</surname>
<given-names>Firas H.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Florida, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">toxicsalama@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>9</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>5</issue>
<elocation-id>e0196436</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>4</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Salama et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0196436"/>
<abstract>
<p>Neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD) are characterized by progressive neuronal loss and pathological accumulation of some proteins. Developing new biomarkers for both diseases is highly important for the early diagnosis and possible development of neuro-protective strategies. Serum antibodies (AIAs) against neuronal proteins are potential biomarkers for AD and PD that may be formed in response to their release into systemic circulation after brain damage. In the present study, two AIAs (tubulin and tau) were measured in sera of patients of PD and AD, compared to healthy controls. Results showed that both antibodies were elevated in patients with PD and AD compared to match controls. Curiously, the profile of elevation of antibodies was different in both diseases. In PD cases, tubulin and tau AIAs levels were similar. On the other hand, AD patients showed more elevation of tau AIAs compared to tubulin. Our current results suggested that AIAs panel could be able to identify cases with neuro-degeneration when compared with healthy subjects. More interestingly, it is possible to differentiate between PD and AD cases through identifying specific AIAs profile for each neurodegenerative states.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100002349</institution-id>
<institution>Academy of Scientific Research and Technology</institution>
</institution-wrap>
</funding-source>
<award-id>2016 JESOR-D</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1644-0273</contrib-id>
<name name-style="western">
<surname>Salama</surname>
<given-names>Mohamed</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>The present work was supported by a grant from Egyptian Academy of Scientific Research and Technology (ASRT) through the program JESOR Development (MS; MAB).</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<page-count count="11"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the commonest neurodegenerative diseases with late diagnosis [<xref ref-type="bibr" rid="pone.0196436.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0196436.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0196436.ref003">3</xref>] and hence their devastating prognosis [<xref ref-type="bibr" rid="pone.0196436.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0196436.ref002">2</xref>]. Clinical diagnosis of PD depends on several motor manifestations, which occur 10–20 years after the beginning of neuro-degeneration and loss of over 60% of dopaminergic neurons [<xref ref-type="bibr" rid="pone.0196436.ref004">4</xref>]. Similarly, pathological changes of AD develop over many years before manifestations of subtle cognitive impairment [<xref ref-type="bibr" rid="pone.0196436.ref005">5</xref>]. This gives a very low chance for development of effective treatment. Thus the discovery of early diagnostic biomarkers could be able to pave the way for discovering a new and effective neuro-protective strategies for these diseases [<xref ref-type="bibr" rid="pone.0196436.ref006">6</xref>].</p>
<p>As in most neurodegenerative states, PD is accompanied by neuronal damage in certain brain areas, namely substantia nigra and striatal dopaminergic system [<xref ref-type="bibr" rid="pone.0196436.ref007">7</xref>]. Likewise, AD is associated with neuronal loss that starts many years before the appearance of clinical manifestations [<xref ref-type="bibr" rid="pone.0196436.ref008">8</xref>]. Neuronal damage leads to the release of some neural proteins that pass through the damaged blood-brain barrier (BBB) and enter the systemic circulation. As these proteins are normally hidden from the body’s immune system, they will be received by humoral immunity as new antigens warranting the formation of autoantibodies (AIAs) against them. Therefore, these formed AIAs could be used as diagnostic peripheral biomarkers in several neurodegenerative diseases including PD and AD [<xref ref-type="bibr" rid="pone.0196436.ref009">9</xref>].</p>
<p>In the recent few years, there has been a growing interest and proof showing that humoral response may be involved in the pathogenesis of neurodegenerative diseases. Consequently, serum AIAs antibodies directed against different self-antigens may play a role in the pathophysiology of different neurodegenerative diseases [<xref ref-type="bibr" rid="pone.0196436.ref010">10</xref>–<xref ref-type="bibr" rid="pone.0196436.ref013">13</xref>]. Although several hypotheses have proposed the elevation of AIAs in patients’ sera, little attention has been paid for their use as biomarkers for diagnosis of PD [<xref ref-type="bibr" rid="pone.0196436.ref014">14</xref>–<xref ref-type="bibr" rid="pone.0196436.ref016">16</xref>]. The choice of AIAs panel depends on their role in the pathogenesis of a disease, hence the possibility of damage and release during the course of such disease [<xref ref-type="bibr" rid="pone.0196436.ref017">17</xref>,<xref ref-type="bibr" rid="pone.0196436.ref018">18</xref>]. One class of neuronal proteins that has a strong correlation to central nervous system (CNS) homeostasis and function is the microtubules group [<xref ref-type="bibr" rid="pone.0196436.ref019">19</xref>].</p>
<p>Microtubules (MTs) are polymers of α/β-tubulin heterodimers [<xref ref-type="bibr" rid="pone.0196436.ref020">20</xref>]. MTs are involved in many cellular functions e.g. cell division and cellular transport, through interaction with the so-called MT-associated proteins [<xref ref-type="bibr" rid="pone.0196436.ref021">21</xref>]. Therefore, it was hypothesized that neurons express their distinctive morphology through support by intra-neuronal MT-dependent networks [<xref ref-type="bibr" rid="pone.0196436.ref022">22</xref>]. It is noteworthy to mention that one important step in axonal degeneration is the dying-back phenomenon [<xref ref-type="bibr" rid="pone.0196436.ref023">23</xref>]. In this detrimental process, axonal degeneration begins distally back to the cell body in what is called <italic>axon retraction model</italic> [<xref ref-type="bibr" rid="pone.0196436.ref023">23</xref>]. The later seems to be initiated by disruption of neural cytoskeleton through defective MTs as reported previously [<xref ref-type="bibr" rid="pone.0196436.ref024">24</xref>,<xref ref-type="bibr" rid="pone.0196436.ref025">25</xref>] and confirmed by findings in several neurodegenerative conditions[<xref ref-type="bibr" rid="pone.0196436.ref026">26</xref>]. Based on the aforementioned notions, defects in tubulin (e.g. genetic abnormalities in its genes) could lead to several neurological states [<xref ref-type="bibr" rid="pone.0196436.ref027">27</xref>–<xref ref-type="bibr" rid="pone.0196436.ref029">29</xref>]. It is interesting to highlight that the dying back phenomenon plays an important role in PD neuronal death [<xref ref-type="bibr" rid="pone.0196436.ref030">30</xref>]. It was therefore hypothesized that there is a strong correlation between MTs and PD related protein such as leucine-rich repeat kinase 2 (LRRK2), synuclein, and Parkin [<xref ref-type="bibr" rid="pone.0196436.ref031">31</xref>,<xref ref-type="bibr" rid="pone.0196436.ref032">32</xref>].</p>
<p>Turning to another class of cytoskeletal proteins that has been deeply involved in regulation of MTs function, which is the Microtubule Associated Proteins (MAPs). Quite recently, considerable attention has been paid to study the role of Tau in neuro-degeneration [<xref ref-type="bibr" rid="pone.0196436.ref033">33</xref>]. Tau was reported to play a vital role in AD pathogenesis as well as in a group of other disorders that share tau protein abnormalities, hence, named collectively “tauopathies” [<xref ref-type="bibr" rid="pone.0196436.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0196436.ref035">35</xref>]. More interestingly, tau was proved to be involved in PD as well [<xref ref-type="bibr" rid="pone.0196436.ref036">36</xref>]. In the present study, we explore the possibility of using a panel of AIAs against two MTs related proteins; Tubulin (TUB) and Microtubule-Associated Protein Tau (TAU), as potential peripheral biomarkers for diagnosis of PD and AD.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Patients recruitment</title>
<p>Twenty-six PD; 15 AD and 10 healthy subjects (as controls) were recruited for the current cross-sectional study from Ain Shams University, Movement Disorders Clinic and Okasha Institute of Psychiatry, Egypt. Subjects were exposed to comprehensive medical examination to confirm the staging and scoring of each disease. Controls were examined as well to exclude the possibility of any other neurodegenerative disorders.</p>
<p>Recruited PD patients were diagnosed according to the British Parkinson ‘s Disease Society Brain Bank criteria [<xref ref-type="bibr" rid="pone.0196436.ref037">37</xref>]. Staging of PD was done using the Unified Parkinson’s Disease Rating Scale (UPDRS), Hoehn and Yahr scale (H&amp;Y), and Schwab and England scales (S &amp; E) in “medication Off” and “On” states. Patients’ exclusion criteria included presence of dementia, atypical or secondary parkinsonism. Vis-à-vis AD Patients were diagnosed according to the NINCDS-ADRDA and DSM-IV criteria for dementia [<xref ref-type="bibr" rid="pone.0196436.ref038">38</xref>] and assessed using the Arabic version of the Montreal Cognitive Assessment (MoCA) test [<xref ref-type="bibr" rid="pone.0196436.ref039">39</xref>,<xref ref-type="bibr" rid="pone.0196436.ref040">40</xref>]</p>
<p>The study was approved by the Institutional Review Board (IRB) of Mansoura School of Medicine, and Ethical Committee of Faculty of Medicine, Ain Shams University. All participants signed informed consent prior to the enrolment in our study.</p>
<p>Blood samples were withdrawn from both control and case into anticoagulant-free tubes, then, sera were obtained by centrifugation of blood at 3000 RPM for 20 min at 4 C° then aliquoted and stored at -20 C° (for no more than 1 week) prior to their transfer to the Medical Experimental Research Center (MERC) of Mansoura University and stored at—80 <sup>0</sup>C.</p>
</sec>
<sec id="sec004">
<title>Autoantibodies estimation</title>
<p>All antibodies have been assayed using a MyBioSource<sup>TM</sup> enzyme-linked immunosorbent assay (<italic>ELISA)</italic> kits (San Diego, CA, USA). Serum concentrations of Microtubule-associated Protein Tau antibody (anti-MAPT) and Tubulin Alpha 1B Chain Antibody (TUBA1BA) were determined by quantitative sandwich ELISA (Cat. No. MBS9310801, <ext-link ext-link-type="uri" xlink:href="https://www.mybiosource.com/prods/ELISA-Kit/Human/Tubulin-Alpha-1B-Chain-Antibody-TUBA1BA/TUBA1BA/datasheet.php?products_id=108941" xlink:type="simple">MBS108941</ext-link>, respectively). Testing steps have been carried out according to the manufacturer’s provided protocols. The absorbance was read using an automatic microplate reader (Optica, Mikura Ltd, UK) at 450 nm. The sensitivity of the assay was 0.1 ng/ml.</p>
</sec>
<sec id="sec005">
<title>Data analysis</title>
<p>Data analysis was performed, using Statistical Package for Social Science (SPSS 20), to identify the ability of autoantibodies to separate cases (PD and AD) from controls. Continuous variables were compared using one-way ANOVA followed by post hoc analysis using the Bonferroni test.</p>
<p>To differentiate between controls, PD cases and AD cases, we performed the following analyses methods: individual correlation value for biomarkers, histograms and distribution curves. Correlations between serum levels of AIAs and clinical data of the studied groups using Pearson’s (for parametric data) and Spearman’s (for non-parametric data) coefficients tests.</p>
</sec>
</sec>
<sec id="sec006" sec-type="results">
<title>Results</title>
<sec id="sec007">
<title>Demographic and clinical data of cases</title>
<p>Mean age of PD patients was 52.92 ± 11.98 years old (range 23–69), while the mean age of patients with AD was 71.88 ± 7.0 years old (range 61–81). Males were 50% of recruited subjects of both diseases. <xref ref-type="table" rid="pone.0196436.t001">Table 1</xref> summarizes demographic, clinical and serum autoantibodies data for both patients and control.</p>
<table-wrap id="pone.0196436.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0196436.t001</object-id>
<label>Table 1</label> <caption><title>Demographic, clinical and serum autoantibodies of patients with PD and AD diseases.</title></caption>
<alternatives>
<graphic id="pone.0196436.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0196436.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" style="background-color:#FFFFFF"/>
<th align="center" style="background-color:#FFFFFF">PD Patients; Mean ± SD (n = 26)</th>
<th align="center" style="background-color:#FFFFFF">AD patients; Mean ± SD (n = 15)</th>
<th align="center" style="background-color:#FFFFFF">Controls; Mean ± SD (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify" style="background-color:#FFFFFF">Age (years)</td>
<td align="center" style="background-color:#FFFFFF">52.92 ± 11.98 (range 23–69)</td>
<td align="center" style="background-color:#FFFFFF">71.88 ± 7.0 (range 61–81)</td>
<td align="center" style="background-color:#FFFFFF">61.22 ± 5.4 (range 44–72)</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">DOI (years)</td>
<td align="center" style="background-color:#FFFFFF">5.48 ± 3.03 (1–10)</td>
<td align="center" style="background-color:#FFFFFF">4.47 ± 2.81 (1–9)</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">AOO</td>
<td align="center" style="background-color:#FFFFFF">47.44 ± 11.38 (22–63)</td>
<td align="center" style="background-color:#FFFFFF">67.41 ± 6.19 (59–75)</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">MOCA</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">16.13±5.20</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">H&amp;Y off</td>
<td align="center" style="background-color:#FFFFFF">3.33±1.19</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">H&amp;Y on</td>
<td align="center" style="background-color:#FFFFFF">1.54±1.15</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">S&amp;E OFF</td>
<td align="center" style="background-color:#FFFFFF">45.00±26.04</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">S&amp;E ON</td>
<td align="center" style="background-color:#FFFFFF">80.42±18.99</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">UPDRS I off</td>
<td align="center" style="background-color:#FFFFFF">5.42±2.60</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">UPDRS II off</td>
<td align="center" style="background-color:#FFFFFF">24.74±12.17</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">UPDRS III off</td>
<td align="center" style="background-color:#FFFFFF">50.79±17.42</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
<td align="center" style="background-color:#FFFFFF">——————</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">TUB AIAs</td>
<td align="center" style="background-color:#FFFFFF">4.04 ± 0.30<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="center" style="background-color:#FFFFFF">3,92 ± 0.26<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="center" style="background-color:#FFFFFF">0.228 ± 0.50</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF">Tau AIAs</td>
<td align="center" style="background-color:#FFFFFF">3.93 ± 0.28<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="center" style="background-color:#FFFFFF">7.72 ± 6.20<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="center" style="background-color:#FFFFFF">0.45 ± 0.50</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>SD, standard deviation; H&amp;Y, Hoehn and Yahr Scale; S&amp;E, Schwab and England Scale, UPDRS, Unified Parkinson’s Disease Rating Scale, AIAs; autoantibodies</p></fn>
<fn id="t001fn002"><p>* = P &lt; 0.001 compared to control.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec008">
<title>Autoantibodies levels</title>
<p>The results of both tested AIAs showed statistically significant elevation in both diseases (PD and AD) compared to controls (p&lt; 0.001) (<xref ref-type="supplementary-material" rid="pone.0196436.s001">S1 Table</xref>). Post-Hoc analysis showed non-significant differences between PD and AD regarding serum AIAs of Tau (p = 0.069) and Tubulin (p = 1.00).</p>
</sec>
<sec id="sec009">
<title>Correlation values</title>
<p>From the data analysis, we could differentiate patients from controls where tubulin has the highest correlation to the cases (r = 0.629 for tubulin and r = 0.327 for tau).</p>
<p>Tubulin AIAs level was a true differential factor between patients and control, wherein controls tubulin AIAs were not significant. In other words, when tubulin AIAs were detected in sera then it was an indication of a neurodegenerative disease as seen in “<xref ref-type="fig" rid="pone.0196436.g001">Fig 1</xref>”. Tau AIAs also showed the ability to differentiate patients from controls as seen in “<xref ref-type="fig" rid="pone.0196436.g001">Fig 1</xref>”. Serum Tau AIAs were significantly correlated to duration of illness (r = 0.563, p = 0.029) in patients with AD, and a trend for significance with MOCA scores (r = -0.490, p = 0.061), while tubulin serum AIAs did not show significant correlation. MOCA was correlated to the age of patients (r = 0.916, p = 0.013), and age of onset (r = -0.519, p = 0.039). Both AIAs did not show a significant correlation with UPDRS III off, H &amp; Y off, and S&amp; E off scales among PD patients.</p>
<fig id="pone.0196436.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0196436.g001</object-id>
<label>Fig 1</label>
<caption>
<title/>
<p><bold>Serum autoantibodies titers of Tubulin (A) and Tau (B) in investigated groups.</bold> Higher levels of both AIAs were higher in patients of PD and AD compared to controls.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0196436.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec010">
<title>Histograms</title>
<p>From the histograms “<xref ref-type="fig" rid="pone.0196436.g002">Fig 2</xref>”, we can easily separate patients from control using the biomarkers. Regarding differentiation between different diseases, most of PD patients showed a similar elevation for tubulin and tau AIAs levels. On the other hand, AD patients showed higher values of Tau AIAs compared to tubulin AIAs.</p>
<fig id="pone.0196436.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0196436.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Histograms showing levels of autoantibodies in different groups (mean ± SEM).</title>
<p>Tubulin AIAs show a significant elevation in PD and AD cases compared to control. On the other hands, Tau was elevated in both diseases with higher elevation in AD.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0196436.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec011">
<title>Level distribution curves</title>
<p>Distribution curves showed possible classification of studied samples into three distinctive groups (based on the identification of peaks representing clusters of cases) as follows:</p>
<p>“<xref ref-type="fig" rid="pone.0196436.g003">Fig 3A</xref>” illustrates the distribution curve for tubulin AIAs. As can be seen from this figure, there are 3 groups: group 1: control—from 1 to 1.2; group 2 –from 1.2 to 6; and group 3 –from 6 upwards. Combining data from the curve to previous histogram graphs, group 2 should be AD and group 3 should be PD.</p>
<fig id="pone.0196436.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0196436.g003</object-id>
<label>Fig 3</label>
<caption>
<title/>
<p><bold>Distribution curves of AIAs against tubulin (3A), tau (3B) and the combination of tubulin and tau (3C) in different groups.</bold> Curves showed possible differentiation between cases and controls (3A and 3B) and the possibility of identifying profiles specific for PD and AD (Tubulin in blue and Tau in red) (3C).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0196436.g003" xlink:type="simple"/>
</fig>
<p>As shown in “<xref ref-type="fig" rid="pone.0196436.g003">Fig 3B</xref>”, tau distribution curve yielded 3 groups: group 1 –control—from 0 to 1.2; group 2 –from 1.2 to 8; and group 3 –from 8 upwards. Here AD range exceeds the curve and from previous histogram graphs, group 2 should be PD and group 3 should be AD.</p>
<p>Plotting data from both AIAs “<xref ref-type="fig" rid="pone.0196436.g003">Fig 3C</xref>” showed possible differentiation between cases and controls. Moreover, the curve shows the possibility of identifying different distribution profiles specific for PD and AD. (Tubulin in blue and Tau in red).</p>
</sec>
</sec>
<sec id="sec012" sec-type="conclusions">
<title>Discussion</title>
<p>This paper is a modest contribution to the ongoing discussion on peripheral biomarkers for diagnosis of PD and AD. In the present report, we have evaluated a panel of two autoantibodies against MTs related proteins (Tubulin and Tau) as peripheral biomarkers for diagnosis of PD and AD. Our results showed that this small panel could differentiate patients from matched controls as evidenced by statistically significant elevation in the two autoantibodies levels among selected patients. Likewise, the panel showed a specific profile for each disease, hence, its benefit in differentiation between PD and AD.</p>
<p>There is a necessity for developing biomarkers that can help in early diagnosis of neurodegenerative diseases, including PD and AD [<xref ref-type="bibr" rid="pone.0196436.ref041">41</xref>]. Since conventional diagnostic tools could not identify in early stages, it is essential to use novel methods [<xref ref-type="bibr" rid="pone.0196436.ref006">6</xref>]. One promising approach is detecting serum autoantibodies against neural proteins involved in the pathogenesis of these disorders [<xref ref-type="bibr" rid="pone.0196436.ref042">42</xref>]. Quantification of these autoantibodies would be an easy, accessible and cost-efficient biomarker for neurodegenerative diseases [<xref ref-type="bibr" rid="pone.0196436.ref043">43</xref>]. The ideal biomarker should be sensitive and specific that it should identify every case compared to controls; meanwhile, it should also differentiate between similar diseases [<xref ref-type="bibr" rid="pone.0196436.ref044">44</xref>].</p>
<p>A challenge in choosing autoantibodies is to identify certain neural proteins that play important role in brain functions and affected in neurodegenerative diseases [<xref ref-type="bibr" rid="pone.0196436.ref045">45</xref>]. Our paper presents an innovated view of the two neural proteins related to microtubules that are deeply involved in the maintenance of cell integrity and function in the brain. Tubulin is the main protein in MTs system [<xref ref-type="bibr" rid="pone.0196436.ref021">21</xref>], as such, it is predicted that in cases of neural damage, tubulin will be affected. More important, tubulin has been proved to be involved in degeneration processes in PD and was linked to PD inducing toxins and related proteins [<xref ref-type="bibr" rid="pone.0196436.ref030">30</xref>–<xref ref-type="bibr" rid="pone.0196436.ref032">32</xref>].</p>
<p>We have addressed not only Tubulin but also Tau. The latter is an associated protein with MTs, hence it compliments the function to tubulin [<xref ref-type="bibr" rid="pone.0196436.ref036">36</xref>] though being involved in many neurodegenerative diseases beginning from AD, tauopathy group of diseases and even PD [<xref ref-type="bibr" rid="pone.0196436.ref035">35</xref>]. This suggests different profiling of Tau compared to tubulin, which would serve for differentiating between different diseases when using both AIAs.</p>
<p>In this report, tubulin was elevated in both diseases (PD and AD), which was anticipated based on the role of MTs in the stabilization of axonal cytoskeleton and neuronal connections [<xref ref-type="bibr" rid="pone.0196436.ref046">46</xref>]. Carletti et al. reported that gluta-thionylation of microtubules (e.g. tubulin) is the initiatory step for oxidative stress-induced damage of the neuronal cytoskeleton, hence, the dying back pattern of axonal degeneration [<xref ref-type="bibr" rid="pone.0196436.ref047">47</xref>]. Niwa et al confirmed the same later where they showed severe neuronal damage in cases of tubulin mutations [<xref ref-type="bibr" rid="pone.0196436.ref048">48</xref>].</p>
<p>The second estimated AIA, (tau), was elevated in both diseases, however, the higher values of tau AIAs were in AD cases compared to PD, which is justifiable by the pivotal role played by tau in AD pathogenesis [<xref ref-type="bibr" rid="pone.0196436.ref033">33</xref>]. More recently, tau levels showed to be high in CSF and sera of AD patients [<xref ref-type="bibr" rid="pone.0196436.ref049">49</xref>–<xref ref-type="bibr" rid="pone.0196436.ref050">50</xref>]. Additionally, we found that serum tau AIA was related to disease duration and MOCA scores (trend for significance) in AD patients. This is in line with earlier studies reporting a significant correlation of serum tau AIAs with cognitive functions [<xref ref-type="bibr" rid="pone.0196436.ref050">50</xref>–<xref ref-type="bibr" rid="pone.0196436.ref052">52</xref>]. The elevation of tau autoantibodies in PD patients has also been reported before [<xref ref-type="bibr" rid="pone.0196436.ref045">45</xref>], which may shed light on the plausible role of tau proteins in PD pathogenesis.</p>
<p>It is important to notice that despite the reported non-significant levels of AIAs between AD and PD, both diseases exerted different profiles, which could serve as a differentiation tool between them. To our knowledge, this the first study to report the qualitative changes between levels of AIAs. As can be seen in histograms, PD pattern showed a similar elevation in both AIAs, whereas, AD showed a higher elevation in tau AIAs compared to tubulin (although both AIAs were significantly higher than control). It is noteworthy that using distribution curves in biomarkers study is more suitable since the arithmetic mean is not a robust statistic tool to be applied for distribution studies, but is more suitable for deriving central tendency. This is mainly due to the fact that it could be affected by the variations of the values in the sample (either too small or too large). Distribution curves in our case showed a more differentiating pattern for cases and each disease.</p>
<p>The present findings of increased IgG against tubulin and tau in AD and PD patients show that both proteins could be involved in the pathogenesis of these diseases. A possible interpretation is that these AIAs represent a “<italic>stable signature</italic>” of neuronal damage in PD and AD [<xref ref-type="bibr" rid="pone.0196436.ref009">9</xref>]. On the other hand, the increase in AIAs—specifically against tubulin and tau could be explained by abnormal stimulation of immune system in the course of diseases [<xref ref-type="bibr" rid="pone.0196436.ref010">10</xref>] or a coexistence of immune-mediated polyneuropathy and neuro-degenerative disorders (PD and AD in our current work) [<xref ref-type="bibr" rid="pone.0196436.ref053">53</xref>]. It is claimed that combination of previous roles may be played by AIAs: earlier they are formed as a result of released proteins into systemic circulation through the pathway of neurodegenerative process, later, these AIAs begin to attack brain tissues leading to more neural damage [<xref ref-type="bibr" rid="pone.0196436.ref009">9</xref>].</p>
<p>Since AIAs represent an immunological memory of damaged proteins, they could be validated as "biomarkers of effect/injury" [<xref ref-type="bibr" rid="pone.0196436.ref054">54</xref>]. A question that could be raised here, is the value of such biomarkers for a clinician seeking early diagnosis, and when could they be applied. The answer to this question comes from a better understanding of most neurodegenerative disorders’ pathogenesis, where environmental exposure to risk factors interact actively with genetics to develop most of these disorders e.g. PD [<xref ref-type="bibr" rid="pone.0196436.ref055">55</xref>]. Since the exposure to environmental agents takes a long time until developing overt damage that can be clinically manifested, a validated biomarker of injury will be very useful as a detector of early exposure in the high-risk population. It is important to notice that the threshold of damage -needed to elicit an immune response, hence, the formation of AIAs- is much lower than the intensity of neuronal loss leading to overt clinical symptoms of the disease [<xref ref-type="bibr" rid="pone.0196436.ref009">9</xref>]. This may be the motive beyond the recommendations issued by Alzheimer's Association and the Alzheimer's Drug Discovery Foundation in 2012 advocating the need for peripheral, non-invasive blood-based biomarker that can diagnose the disease earlier than clinical signs [<xref ref-type="bibr" rid="pone.0196436.ref056">56</xref>]. We believe that AIAs could detect earlier brain damages years before clinical manifestations.</p>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Conclusion</title>
<p>To conclude, our panel -composed of two AIAs- was able to diagnose PD and AD (i.e. differentiating cases from controls). In addition, profiling different diseases seem possible. The profile of elevated AIAs in PD was different from AD with a possibility of individualization, hence specificity in the diagnosis of various neurodegenerative disorders. Needless to say, the main limitation of the current report is the small number of studied cases. We believe that recruiting a larger number of cases will, certainly, confirm our data. Nevertheless, our findings present the first report on using tubulin and tau AIAs as peripheral biomarkers for diagnosis of PD or AD.</p>
</sec>
<sec id="sec014">
<title>Supporting information</title>
<supplementary-material id="pone.0196436.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0196436.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Table showing individual AIAs levels in patients and controls.</title>
<p>Dataset supporting the individual cases and controls values were uploaded to the Journal submission system.</p>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The present work was supported by a grant from Egyptian Academy of Scientific Research and Technology (ASRT) through the program JESOR Development.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0196436.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Lau</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Breteler</surname> <given-names>MM</given-names></name> (<year>2006</year>) <article-title>Epidemiology of Parkinson's disease</article-title>. <source><italic>Lancet Neurol</italic></source>. <volume>5</volume>(<issue>6</issue>): <fpage>525</fpage>–<lpage>535</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(06)70471-9" xlink:type="simple">10.1016/S1474-4422(06)70471-9</ext-link></comment> <object-id pub-id-type="pmid">16713924</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>Alzheimer’s Association</collab>. (<year>2015</year>) <article-title>Alzheimer’s disease facts and figures</article-title>. <source>Alzheimer’s Dement</source>. <volume>11</volume>:<fpage>332</fpage>–<lpage>384</lpage>.To</mixed-citation></ref>
<ref id="pone.0196436.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beaach</surname> <given-names>TG</given-names></name> (<year>2017</year>) <article-title>A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?</article-title>. <source>Neurol. Ther</source>. <volume>6</volume>(<issue>Suppl 1</issue>): <fpage>5</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40120-017-0072-x" xlink:type="simple">10.1007/s40120-017-0072-x</ext-link></comment> <object-id pub-id-type="pmid">28733961</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stocchi</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Vacca</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Radicati</surname> <given-names>FG</given-names></name> (<year>2015</year>) <article-title>How to optimize the treatment of early stage Parkinson’s disease</article-title>. <source>Transl. Neurodegener</source>. <volume>4</volume> (<issue>4</issue>): <fpage>9158</fpage>.</mixed-citation></ref>
<ref id="pone.0196436.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dumurgier</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hanseeuw</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Hatling</surname> <given-names>FB</given-names></name>, <name name-style="western"><surname>Judge</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Schultz</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Chhatwal</surname> <given-names>JP</given-names></name>, <etal>et al</etal>. (<year>2017</year>) <article-title>Alzheimer’s Biomarkers and Future Decline in Cognitive Normal Older Adults</article-title>. <source>J. Alzheimers Dis</source>. <volume>60</volume>(<issue>4</issue>): <fpage>1451</fpage>–<lpage>1459</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3233/JAD-170511" xlink:type="simple">10.3233/JAD-170511</ext-link></comment> <object-id pub-id-type="pmid">29036824</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Papuć</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Rejdak</surname> <given-names>K</given-names></name> (<year>2017</year>) <article-title>Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonism</article-title>. <source>J. Neural Transm. (Vienna)</source> <volume>124</volume>(<issue>2</issue>): <fpage>209</fpage>–<lpage>216</lpage>.</mixed-citation></ref>
<ref id="pone.0196436.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sengupta</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Guerrero-Muñoz</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Castillo-Carranza</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Lasagna-Reeves</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Gerson</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Paulucci-Holthauzen</surname> <given-names>AA</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies</article-title>. <source>Biol. Psychiatry</source> <volume>78</volume>(<issue>10</issue>): <fpage>672</fpage>–<lpage>683</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.biopsych.2014.12.019" xlink:type="simple">10.1016/j.biopsych.2014.12.019</ext-link></comment> <object-id pub-id-type="pmid">25676491</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Petersen</surname> <given-names>RC</given-names></name> (<year>2009</year>. <article-title>Early diagnosis of Alzheimer’s disease: is MCI too late?</article-title> <source>Curr. Alzheimer Res</source>. <volume>6</volume>:<fpage>324</fpage>–<lpage>330</lpage>. <object-id pub-id-type="pmid">19689230</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elfawal</surname> <given-names>HA</given-names></name> (<year>2014</year>) <article-title>Neuroantibody biomarkers: links and challenges in environmental neurodegeneration and autoimmunity</article-title>. <source>Autoimmune Dis</source>. <volume>2014</volume>:<fpage>340875</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2014/340875" xlink:type="simple">10.1155/2014/340875</ext-link></comment> <object-id pub-id-type="pmid">25045531</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maetzler</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Apel</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Langkamp</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Deuschle</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Dilger</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Stimkorb</surname> <given-names>JG</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls</article-title>. <source>PLoS One</source> <volume>9</volume>(<issue>2</issue>): <fpage>e88604</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0088604" xlink:type="simple">10.1371/journal.pone.0088604</ext-link></comment> <object-id pub-id-type="pmid">24586351</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maetzler</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Berg</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Synofzik</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Brockmann</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Godau</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Melms</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias</article-title>. <source>J. Alzheimers Dis</source>. <volume>26</volume>: <fpage>171</fpage>–<lpage>179</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3233/JAD-2011-110221" xlink:type="simple">10.3233/JAD-2011-110221</ext-link></comment> <object-id pub-id-type="pmid">21593566</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monahan</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Warren</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Carvey</surname> <given-names>PM</given-names></name> (<year>2008</year>) <article-title>Neuroinflammation and peripheral immune infiltration in Parkinson’s disease: an autoimmune hypothesis</article-title>. <source>Cell Transplant</source>. <volume>17</volume>: <fpage>363</fpage>–<lpage>367</lpage>. <object-id pub-id-type="pmid">18522239</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shalash</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Salama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Makar</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Roushdy</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Elrassas</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Mohamed</surname> <given-names>W</given-names></name>, <etal>et al</etal>. (<year>2017</year>) <article-title>Elevated Serum alpha-synuclein autoantibodies in patients with Parkinson’s disease relative to Alzheimer’s disease and controls</article-title>. <source>Front. Neurol</source>. <volume>8</volume>:<fpage>720</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fneur.2017.00720" xlink:type="simple">10.3389/fneur.2017.00720</ext-link></comment> <object-id pub-id-type="pmid">29312137</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Masliah</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Rockenstein</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mante</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Crews</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Spencer</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Adame</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease</article-title>. <source>PLoS One</source> <volume>6</volume>: <fpage>e19338</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0019338" xlink:type="simple">10.1371/journal.pone.0019338</ext-link></comment> <object-id pub-id-type="pmid">21559417</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vekrellis</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Stefanis</surname> <given-names>L</given-names></name> (<year>2012</year>) <article-title>Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson’s disease and other synucleinopathies</article-title>. <source>Expert Opin. Ther. Targets</source> <volume>16</volume>: <fpage>421</fpage>–<lpage>432</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1517/14728222.2012.674111" xlink:type="simple">10.1517/14728222.2012.674111</ext-link></comment> <object-id pub-id-type="pmid">22480256</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wootla</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Watzlawik</surname> <given-names>JO</given-names></name>, <name name-style="western"><surname>Warrington</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Wittenberg</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Denic</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jordan</surname> <given-names>LR</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Naturally occurring monoclonal antibodies and their therapeutic potential for neurologic diseases</article-title>. <source>JAMA Neurol</source>. <volume>72</volume>: <fpage>1346</fpage>–<lpage>1353</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamaneurol.2015.2188" xlink:type="simple">10.1001/jamaneurol.2015.2188</ext-link></comment> <object-id pub-id-type="pmid">26389734</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abd El Rahman</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Salama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gad El-Hak</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>El-Harouny</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Elkafrawy</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Abou-Donia</surname> <given-names>MB</given-names></name>. (<year>2017</year>) <article-title>A panel of autoantibodies against neural proteins as peripheral biomarker for pesticides-induced neurotoxicity</article-title>. <source>Neurotox. Res</source>. <volume>33</volume>(<issue>2</issue>):<fpage>316</fpage>–<lpage>336</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12640-017-9793-y" xlink:type="simple">10.1007/s12640-017-9793-y</ext-link></comment> <object-id pub-id-type="pmid">28875469</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abou-Donia</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Conboy</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Kokkotou</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Jacobson</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Elmasry</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Elkafrawy</surname> <given-names>P</given-names></name>, <etal>et al</etal>. (<year>2017</year>) <article-title>Screening for novel central nervous system biomarkers in veterans with Gulf War Illness</article-title>. <source>Neurotoxicol. Teratol</source>. <volume>61</volume>: <fpage>36</fpage>–<lpage>46</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ntt.2017.03.002" xlink:type="simple">10.1016/j.ntt.2017.03.002</ext-link></comment> <object-id pub-id-type="pmid">28286177</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nogales</surname> <given-names>E</given-names></name> (<year>2001</year>) <article-title>Structural insight into microtubule function</article-title>. <source>Annu. Rev. Biophys. Biomol. Struct</source>. <volume>30</volume>: <fpage>397</fpage>–<lpage>420</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1146/annurev.biophys.30.1.397" xlink:type="simple">10.1146/annurev.biophys.30.1.397</ext-link></comment> <object-id pub-id-type="pmid">11441808</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mitchison</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kirschner</surname> <given-names>M</given-names></name> (<year>1984</year>) <article-title>Dynamic instability of microtubule growth</article-title>. <source>Nature</source> <volume>312</volume>(<issue>5991</issue>): <fpage>237</fpage>–<lpage>242</lpage>. <object-id pub-id-type="pmid">6504138</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sirajuddin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rice</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Vale</surname> <given-names>RD</given-names></name> (<year>2014</year>) <article-title>Regulation of microtubule motors by tubulin isotypes and post-translational modifications</article-title>. <source>Nat. Cell. Biol</source>. <volume>16</volume>(<issue>4</issue>): <fpage>335</fpage>–<lpage>344</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncb2920" xlink:type="simple">10.1038/ncb2920</ext-link></comment> <object-id pub-id-type="pmid">24633327</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hirokawa</surname> <given-names>N</given-names></name> (<year>1982</year>) <article-title>Cross-linker system between neurofilaments, microtubules, and membranous organelles in frog axons revealed by the quick-freeze, deep-etching method</article-title>. <source>J. Cell Biol</source>. <volume>94</volume>: <fpage>129</fpage>–<lpage>142</lpage>. <object-id pub-id-type="pmid">6181077</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gillingwater</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Ribchester</surname> <given-names>RR</given-names></name> (<year>2003</year>) <article-title>The relationship of neuromuscular synapse elimination to synaptic degeneration and pathology: insights from WldS and other mutant mice</article-title>. <source>J. Neurocytol</source>. <volume>32</volume>(<issue>5–8</issue>): <fpage>863</fpage>–<lpage>881</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1023/B:NEUR.0000020629.51673.f5" xlink:type="simple">10.1023/B:NEUR.0000020629.51673.f5</ext-link></comment> <object-id pub-id-type="pmid">15034273</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Solomon</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Magendantz</surname> <given-names>M</given-names></name> (<year>1981</year>) <article-title>Cytochalasin separates microtubule disassembly from loss of asymmetric morphology</article-title>. <source>J. Cell Biol</source>. <volume>89</volume>(<issue>1</issue>): <fpage>157</fpage>–<lpage>161</lpage>. <object-id pub-id-type="pmid">7014572</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baas</surname> <given-names>PW</given-names></name>, <name name-style="western"><surname>Ahmad</surname> <given-names>FJ</given-names></name> (<year>2001</year>) <article-title>Force generation by cytoskeletal motor proteins as a regulator of axonal elongation and retraction</article-title>. <source>Trends Cell Biol</source>. <volume>11</volume>(<issue>6</issue>): <fpage>244</fpage>–<lpage>249</lpage>. <object-id pub-id-type="pmid">11356360</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vickers</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>King</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Woodhouse</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kirkcaldie</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Staal</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>McCormack</surname> <given-names>GH</given-names></name>, <etal>et al</etal>. (<year>2009</year>). <article-title>Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system</article-title>. <source>Brain Res. Bull</source>. <volume>80</volume>(<issue>4–5</issue>): <fpage>217</fpage>–<lpage>223</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.brainresbull.2009.08.004" xlink:type="simple">10.1016/j.brainresbull.2009.08.004</ext-link></comment> <object-id pub-id-type="pmid">19683034</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jaglin</surname> <given-names>XH</given-names></name>, <name name-style="western"><surname>Poirier</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Saillour</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Buhler</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Tian</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bahi-Buisson</surname> <given-names>N</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria</article-title>. <source>Nat. Genet</source>. <volume>41</volume>: <fpage>746</fpage>–<lpage>752</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.380" xlink:type="simple">10.1038/ng.380</ext-link></comment> <object-id pub-id-type="pmid">19465910</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Poirier</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Saillour</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Bahi-Buisson</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Jaglin</surname> <given-names>XH</given-names></name>, <name name-style="western"><surname>Fallet-Bianco</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Nabbout</surname> <given-names>R</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Mutations in the neuronal _-tubulin subunit TUBB3 result in malformation of cortical development and neuronal migration defects</article-title>. <source>Hum. Mol. Genet</source>. <volume>19</volume>: <fpage>4462</fpage>–<lpage>4473</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/ddq377" xlink:type="simple">10.1093/hmg/ddq377</ext-link></comment> <object-id pub-id-type="pmid">20829227</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tischfield</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Baris</surname> <given-names>HN</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Rudolph</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Van Maldergem</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>W</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance</article-title>. <source>Cell</source> <volume>140</volume>: <fpage>74</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2009.12.011" xlink:type="simple">10.1016/j.cell.2009.12.011</ext-link></comment> <object-id pub-id-type="pmid">20074521</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cappelletti</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Casagrande</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Calogero</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>De Gregorio</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pezzoli</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Cartelli</surname> <given-names>D</given-names></name>. (<year>2015</year>) <article-title>Linking microtubules to Parkinson's disease: the case of parkin</article-title>. <source>Biochem. Soc. Trans</source>. <volume>43</volume>(<issue>2</issue>): <fpage>292</fpage>–<lpage>296</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1042/BST20150007" xlink:type="simple">10.1042/BST20150007</ext-link></comment> <object-id pub-id-type="pmid">25849932</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Esteves</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Gozes</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Cardoso</surname> <given-names>SM</given-names></name> (<year>2014</year>) <article-title>The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease</article-title>. <source>Biochim. Biophys. Acta</source>. <volume>1842</volume>(<issue>1</issue>): <fpage>7</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbadis.2013.10.003" xlink:type="simple">10.1016/j.bbadis.2013.10.003</ext-link></comment> <object-id pub-id-type="pmid">24120997</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cartelli</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Cappelletti</surname> <given-names>G</given-names></name> (<year>2016</year>) <article-title>Microtubule Destabilization Paves the Way to Parkinson's Disease</article-title>. <source>Mol. Neurobiol</source>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12035-016-0188-5" xlink:type="simple">10.1007/s12035-016-0188-5</ext-link></comment> (Epub). <object-id pub-id-type="pmid">27757833</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kambe</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Motoi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Inoue</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kojima</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Tada</surname> <given-names>N</given-names></name>, (<year>2011</year>) <article-title>Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice</article-title>. <source>Neurobiol. Dis</source>. <volume>42</volume>(<issue>3</issue>): <fpage>404</fpage>–<lpage>414</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nbd.2011.02.002" xlink:type="simple">10.1016/j.nbd.2011.02.002</ext-link></comment> <object-id pub-id-type="pmid">21324362</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ludolph</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Kassubek</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Landwehrmeyer</surname> <given-names>BG</given-names></name>, <name name-style="western"><surname>Mandelkow</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mandelkow</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Burn</surname> <given-names>DJ</given-names></name>, <etal>et al</etal>.: <article-title>Reisensburg Working Group for Tauopathies With Parkinsonism. (2009) Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options</article-title>. <source>Eur. J. Neurol</source>. <volume>16</volume>(<issue>3</issue>): <fpage>297</fpage>–<lpage>309</lpage>.</mixed-citation></ref>
<ref id="pone.0196436.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takenokuchi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kadoyama</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Chiba</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sumida</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Matsuyama</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Saigo</surname> <given-names>K</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>SJLB mice develop tauopathy-induced parkinsonism</article-title>. <source>Neuroscience Letters</source> <volume>473</volume>: <fpage>182</fpage>–<lpage>185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neulet.2010.02.032" xlink:type="simple">10.1016/j.neulet.2010.02.032</ext-link></comment> <object-id pub-id-type="pmid">20178834</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lei</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ayton</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Finkelstein</surname> <given-names>DI</given-names></name>, <name name-style="western"><surname>Adlard</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Masters</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Bush</surname> <given-names>AI</given-names></name>. (<year>2010</year>) <article-title>Tau protein: relevance to Parkinson's disease</article-title>. <source>Int. J. Biochem. Cell. Biol</source>. <volume>42</volume>(<issue>11</issue>): <fpage>1775</fpage>–<lpage>1778</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.biocel.2010.07.016" xlink:type="simple">10.1016/j.biocel.2010.07.016</ext-link></comment> <object-id pub-id-type="pmid">20678581</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hughes</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Daniel</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Kilford</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lees</surname> <given-names>AJ</given-names></name> (<year>1992</year>) <article-title>Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source> <volume>55</volume>: <fpage>181</fpage>–<lpage>184</lpage>. <object-id pub-id-type="pmid">1564476</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McKhann</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Knopman</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Chertkow</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hyman</surname> <given-names>BT</given-names></name>, <name name-style="western"><surname>Jack</surname> <given-names>CR</given-names> <suffix>Jr</suffix></name>, <name name-style="western"><surname>Kawas</surname> <given-names>CH</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <volume>7</volume>: <fpage>263</fpage>–<lpage>269</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jalz.2011.03.005" xlink:type="simple">10.1016/j.jalz.2011.03.005</ext-link></comment> <object-id pub-id-type="pmid">21514250</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nasreddine</surname> <given-names>ZS</given-names></name>, <name name-style="western"><surname>Phillips</surname> <given-names>NA</given-names></name>, <name name-style="western"><surname>Bédirian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Charbonneau</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Whitehead</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Collin</surname> <given-names>I</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J. Am. Geriatr. Soc</source>. <volume>53</volume>(<issue>4</issue>): <fpage>695</fpage>–<lpage>699</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1532-5415.2005.53221.x" xlink:type="simple">10.1111/j.1532-5415.2005.53221.x</ext-link></comment> <object-id pub-id-type="pmid">15817019</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rahman</surname> <given-names>TT</given-names></name>, <name name-style="western"><surname>El Gaafary</surname> <given-names>MM</given-names></name> (<year>2009</year>) <article-title>Montreal Cognitive Assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo</article-title>. <source>Geriatr. Gerontol. Int</source>. <volume>9</volume>(<issue>1</issue>): <fpage>54</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1447-0594.2008.00509.x" xlink:type="simple">10.1111/j.1447-0594.2008.00509.x</ext-link></comment> <object-id pub-id-type="pmid">19260980</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de la Fuente-Fernández</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Schulzer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kuramoto</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Cragg</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ramachandiran</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Au</surname> <given-names>WL</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease</article-title>. <source>Ann. Neurol</source>. <volume>69</volume>: <fpage>803</fpage>–<lpage>810</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ana.22284" xlink:type="simple">10.1002/ana.22284</ext-link></comment> <object-id pub-id-type="pmid">21246604</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El-Fawal</surname> <given-names>HA</given-names></name>, <name name-style="western"><surname>McCain</surname> <given-names>WC</given-names></name> (<year>2008</year>) <article-title>Antibodies to neural proteins in organophosphorus-induced delayed neuropathy (OPIDN) and its amelioration. Neurotoxicol</article-title>. <source>Teratol</source>. <volume>30</volume>(<issue>3</issue>): <fpage>161</fpage>–<lpage>166</lpage>.</mixed-citation></ref>
<ref id="pone.0196436.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DeMarshall</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sarkar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Nagele</surname> <given-names>EP</given-names></name>, <name name-style="western"><surname>Goldwaser</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Godsey</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Acharya</surname> <given-names>NK</given-names></name>,<etal>et al</etal>. (<year>2015</year>) <article-title>Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases</article-title>. <source>Int. Rev. Neurobiol</source>. <volume>122</volume>: <fpage>1</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/bs.irn.2015.05.005" xlink:type="simple">10.1016/bs.irn.2015.05.005</ext-link></comment> <object-id pub-id-type="pmid">26358889</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DeMarshall</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Nagele</surname> <given-names>EP</given-names></name>, <name name-style="western"><surname>Sarkar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Acharya</surname> <given-names>NK</given-names></name>, <name name-style="western"><surname>Godsey</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Goldwaser</surname> <given-names>EL</given-names></name>, <etal>et al</etal>; <collab>Alzheimer's Disease Neuroimaging Initiative</collab>. (<year>2016</year>). <article-title>Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers</article-title>. <source>Alzheimers Dement. (Amst)</source>. <volume>3</volume>: <fpage>51</fpage>–<lpage>62</lpage>.</mixed-citation></ref>
<ref id="pone.0196436.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kronimus</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Albus</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Balzer-Geldsetzer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Straub</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Semler</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Otto</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2016</year>). <article-title>Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia</article-title>. <source>PLoS One</source> <volume>11</volume>(<issue>11</issue>): <fpage>e0164953</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0164953" xlink:type="simple">10.1371/journal.pone.0164953</ext-link></comment> <object-id pub-id-type="pmid">27802290</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Song</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Brady</surname> <given-names>ST</given-names></name> (<year>2014</year>) <article-title>Stabilization of neuronal connections and the axonal cytoskeleton</article-title>. <source>Bioarchitecture</source> <volume>4</volume>(<issue>1</issue>): <fpage>22</fpage>–<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/bioa.28080" xlink:type="simple">10.4161/bioa.28080</ext-link></comment> <object-id pub-id-type="pmid">24492417</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carletti</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Schopfer</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Colletier</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Froment</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Nachon</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Weik</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Reaction of cresyl saligenin phosphate, the organophosphorus agent implicated in aerotoxic syndrome, with human cholinesterases: mechanistic studies employing kinetics, mass spectrometry, and X-ray structure analysis</article-title>. <source>Chem. Res. Toxicol</source>. <volume>24</volume>(<issue>6</issue>): <fpage>797</fpage>–<lpage>808</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/tx100447k" xlink:type="simple">10.1021/tx100447k</ext-link></comment> <object-id pub-id-type="pmid">21438623</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Niwa</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hirokawa</surname> <given-names>N</given-names></name> (<year>2013</year>) <article-title>β-Tubulin mutations that cause severe neuropathies disrupt axonal transport</article-title>. <source>EMBO J</source>. <volume>32</volume>(<issue>10</issue>): <fpage>1352</fpage>–<lpage>1364</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/emboj.2013.59" xlink:type="simple">10.1038/emboj.2013.59</ext-link></comment> <object-id pub-id-type="pmid">23503589</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Inekci</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Henriksen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Linemann</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Karsdal</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Habib</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bisgaard</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease</article-title>. <source>Curr. Alzheimer Res</source>. <volume>12</volume>(<issue>9</issue>), <fpage>829</fpage>–<lpage>836</lpage>. <object-id pub-id-type="pmid">26159200</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shekhar</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rai</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Singh</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Upadhyay</surname> <given-names>AD</given-names></name>, <etal>et al</etal>. (<year>2016</year>). <article-title>Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients</article-title>. <source>PLoS One</source> <volume>11</volume>(<issue>7</issue>): <fpage>e0159099</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0159099" xlink:type="simple">10.1371/journal.pone.0159099</ext-link></comment> <object-id pub-id-type="pmid">27459603</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chiu</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>TF</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>FP</given-names></name>, <name name-style="western"><surname>Tseng</surname> <given-names>TW</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease</article-title>. <source>Hum Brain Map</source> <volume>35</volume>(<issue>7</issue>): <fpage>3132</fpage>–<lpage>3142</lpage>.</mixed-citation></ref>
<ref id="pone.0196436.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mattsson</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Zetterberg</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Janelidze</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Insel</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Andreasson</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Stomrud</surname> <given-names>E</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Plasma tau in Alzheimer disease</article-title>. <source>Neurology</source> <volume>87</volume>(<issue>17</issue>): <fpage>1827</fpage>–<lpage>1835</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1212/WNL.0000000000003246" xlink:type="simple">10.1212/WNL.0000000000003246</ext-link></comment> <object-id pub-id-type="pmid">27694257</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Toth</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Breithaupt</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ge</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Duan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Terris</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Thiessen</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease</article-title>. <source>Ann Neurol</source>. <volume>68</volume>: <fpage>28e36</fpage>.</mixed-citation></ref>
<ref id="pone.0196436.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El-Fawal</surname> <given-names>H</given-names></name> <article-title>“Neurotoxicology”</article-title> In: <source>Encyclopedia of Environmental Health</source>, Nriagu JO, Ed., vol. <volume>4</volume>, pp. <fpage>87</fpage>–<lpage>106</lpage>, Elsevier, Burlington, Mass, USA, <year>2011</year>.</mixed-citation></ref>
<ref id="pone.0196436.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ascherio</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schwarzschild</surname> <given-names>MA</given-names></name> (<year>2016</year>) <article-title>The epidemiology of Parkinson's disease: risk factors and prevention</article-title>. <source>Lancet neurology</source>. <volume>15</volume>(<issue>12</issue>):<fpage>1257</fpage>–<lpage>1272</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(16)30230-7" xlink:type="simple">10.1016/S1474-4422(16)30230-7</ext-link></comment> <object-id pub-id-type="pmid">27751556</object-id></mixed-citation></ref>
<ref id="pone.0196436.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snyder</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Carrillo</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Grodstein</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Henriksen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Jeromin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lovestone</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Developing novel blood-based biomarkers for Alzheimer’s disease</article-title>. <source>Alzheimers and Dementia</source>, <volume>10</volume>: <fpage>109</fpage>–<lpage>114</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>